JP2010539076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539076A5 JP2010539076A5 JP2010523590A JP2010523590A JP2010539076A5 JP 2010539076 A5 JP2010539076 A5 JP 2010539076A5 JP 2010523590 A JP2010523590 A JP 2010523590A JP 2010523590 A JP2010523590 A JP 2010523590A JP 2010539076 A5 JP2010539076 A5 JP 2010539076A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- derivative
- reacting
- sorafenib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(Nc(cc1C(F)(F)F)ccc1Cl)=O Chemical compound *C(Nc(cc1C(F)(F)F)ccc1Cl)=O 0.000 description 1
- ASPDJZINBYYZRU-UHFFFAOYSA-N Nc(cc1)cc(C(F)(F)F)c1Cl Chemical compound Nc(cc1)cc(C(F)(F)F)c1Cl ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N Nc(cc1)ccc1O Chemical compound Nc(cc1)ccc1O PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- QUZCXFJNKCWQIU-UHFFFAOYSA-N Oc(cc1)ccc1NC(NC1C=C(C(F)(F)F)C(Cl)=CC1)=O Chemical compound Oc(cc1)ccc1NC(NC1C=C(C(F)(F)F)C(Cl)=CC1)=O QUZCXFJNKCWQIU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1733MU2007 | 2007-09-10 | ||
| IN1734MU2007 | 2007-09-10 | ||
| IN1733/MUM/2007 | 2007-09-10 | ||
| IN1734/MUM/2007 | 2007-09-10 | ||
| PCT/GB2008/003048 WO2009034308A2 (en) | 2007-09-10 | 2008-09-10 | Process for the preparation of a raf kinase inhibitor and intermediates for use in the process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539076A JP2010539076A (ja) | 2010-12-16 |
| JP2010539076A5 true JP2010539076A5 (enExample) | 2011-10-27 |
| JP5438680B2 JP5438680B2 (ja) | 2014-03-12 |
Family
ID=40351766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523590A Expired - Fee Related JP5438680B2 (ja) | 2007-09-10 | 2008-09-10 | Ｒａｆキナーゼ阻害剤の製造方法及び該方法に使用する中間体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8445687B2 (enExample) |
| EP (1) | EP2195286A2 (enExample) |
| JP (1) | JP5438680B2 (enExample) |
| KR (1) | KR101553211B1 (enExample) |
| AU (1) | AU2008299703C1 (enExample) |
| CA (1) | CA2698795C (enExample) |
| NZ (1) | NZ583790A (enExample) |
| WO (1) | WO2009034308A2 (enExample) |
| ZA (1) | ZA201001935B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| NZ583790A (en) | 2007-09-10 | 2012-04-27 | Cipla Ltd | Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process |
| PL2344474T3 (pl) | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
| CA2775296A1 (en) | 2009-09-24 | 2011-03-31 | Ranbaxy Laboratories Limited | Polymorphs of sorafenib acid addition salts |
| WO2011036647A1 (en) | 2009-09-24 | 2011-03-31 | Ranbaxy Laboratories Limited | Process for the preparation of sorafenib tosylate |
| WO2011058522A1 (en) | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Sorafenib ethylsulfonate salt, process for preparation and use |
| PL2528899T3 (pl) | 2010-01-29 | 2015-02-27 | Ranbaxy Laboratories Ltd | Solwat sorafenibu z dimetylosulfotlenkiem |
| CN102190616B (zh) * | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
| WO2012098075A1 (en) * | 2011-01-18 | 2012-07-26 | Glaxo Group Limited | Process for the preparation of retigabine |
| CN102485714B (zh) * | 2011-10-09 | 2013-07-24 | 连云港盛和生物科技有限公司 | 一种羰基化合成索拉菲尼的方法 |
| US9173883B2 (en) | 2012-05-21 | 2015-11-03 | Novartis Ag | Ring-substituted N-pyridinyl amides as kinase inhibitors |
| CN103508961B (zh) * | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| CN103408488A (zh) * | 2013-08-13 | 2013-11-27 | 张家港威胜生物医药有限公司 | 一种索拉非尼的优化合成方法 |
| ES2813877T3 (es) | 2013-08-28 | 2021-03-25 | Crown Bioscience Inc Taicang | Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos |
| CN104761492A (zh) * | 2014-01-03 | 2015-07-08 | 正大天晴药业集团股份有限公司 | 对甲苯磺酸索拉非尼的晶型及其制备方法 |
| CN105481764A (zh) * | 2014-09-16 | 2016-04-13 | 重庆圣华曦药业股份有限公司 | 一种索拉非尼对甲苯磺酸盐的制备方法 |
| CN105399668B (zh) * | 2015-12-29 | 2018-11-16 | 开封制药(集团)有限公司 | 一种“一锅法”制备索拉菲尼的方法 |
| CN105801475B (zh) * | 2016-04-25 | 2018-01-12 | 华润双鹤利民药业（济南）有限公司 | 一种甲苯磺酸索拉非尼的制备方法 |
| CN109796400B (zh) * | 2017-11-16 | 2022-07-29 | 四川科伦药物研究院有限公司 | 一种甲苯磺酸索拉菲尼晶型及其制备方法 |
| CN108623521B (zh) * | 2018-03-22 | 2020-09-04 | 盐城师范学院 | 一种乐伐替尼的制备方法 |
| CN108586329A (zh) * | 2018-03-31 | 2018-09-28 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼的合成方法 |
| CN108341770A (zh) * | 2018-03-31 | 2018-07-31 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼化合物的制备方法 |
| CN108276328A (zh) * | 2018-03-31 | 2018-07-13 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼的制备方法 |
| CN108440403A (zh) * | 2018-03-31 | 2018-08-24 | 山东罗欣药业集团恒欣药业有限公司 | 一种瑞戈非尼的制备方法 |
| CN108558747A (zh) * | 2018-03-31 | 2018-09-21 | 山东罗欣药业集团恒欣药业有限公司 | 一种瑞戈非尼的制备方法 |
| CN108276327A (zh) * | 2018-03-31 | 2018-07-13 | 山东罗欣药业集团恒欣药业有限公司 | 一种索拉非尼的制备方法 |
| CN108586330A (zh) * | 2018-04-18 | 2018-09-28 | 日照市普达医药科技有限公司 | 一种治疗肿瘤药物的制备方法及其应用 |
| CA3140017A1 (en) | 2019-07-19 | 2021-01-28 | Aurore HICK | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL123536C (enExample) * | 1963-07-09 | |||
| FR1484461A (fr) * | 1965-06-25 | 1967-06-09 | Grace W R & Co | Compositions herbicides |
| CH50468A4 (enExample) * | 1968-01-12 | 1970-06-30 | ||
| CH490005A (de) * | 1968-02-06 | 1970-05-15 | Ciba Geigy | Schädlingsbekämpfungsmittel |
| BE788983A (fr) * | 1971-09-22 | 1973-01-15 | Rolland Sa A | 3-trifluoromethylanilides |
| US5541224A (en) * | 1994-03-14 | 1996-07-30 | Eli Lilly And Company | Carbanilide anticoccidials |
| EP1158985B1 (en) * | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| PT1140840E (pt) * | 1999-01-13 | 2006-05-31 | Bayer Pharmaceuticals Corp | Difenilureias substituidas com (.)-carboxiarilo como inibidores de raf-quinase |
| US6242385B1 (en) * | 2000-02-28 | 2001-06-05 | Uniroyal Chemical Company, Inc. | Enhancement of seed/fruit/nut yields from flowering plants |
| JP4618127B2 (ja) * | 2003-08-28 | 2011-01-26 | 大正製薬株式会社 | １，３−ジヒドロ−２ｈ−インドール−２−オン誘導体 |
| UY28931A1 (es) | 2004-06-03 | 2005-12-30 | Bayer Pharmaceuticals Corp | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis |
| EP1797037B1 (en) | 2004-09-29 | 2014-12-17 | Bayer HealthCare LLC | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide |
| TW200730503A (en) * | 2005-10-21 | 2007-08-16 | Daiichi Seiyaku Co | Tricyclic compound |
| WO2007064931A2 (en) * | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| NZ583790A (en) | 2007-09-10 | 2012-04-27 | Cipla Ltd | Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process |
-
2008
- 2008-09-10 NZ NZ583790A patent/NZ583790A/en not_active IP Right Cessation
- 2008-09-10 WO PCT/GB2008/003048 patent/WO2009034308A2/en not_active Ceased
- 2008-09-10 CA CA2698795A patent/CA2698795C/en not_active Expired - Fee Related
- 2008-09-10 EP EP08806217A patent/EP2195286A2/en not_active Ceased
- 2008-09-10 AU AU2008299703A patent/AU2008299703C1/en not_active Ceased
- 2008-09-10 US US12/677,195 patent/US8445687B2/en not_active Expired - Fee Related
- 2008-09-10 JP JP2010523590A patent/JP5438680B2/ja not_active Expired - Fee Related
- 2008-09-10 KR KR1020107007688A patent/KR101553211B1/ko not_active Expired - Fee Related
-
2010
- 2010-03-18 ZA ZA2010/01935A patent/ZA201001935B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539076A5 (enExample) | ||
| JP5438680B2 (ja) | Ｒａｆキナーゼ阻害剤の製造方法及び該方法に使用する中間体 | |
| JP2019523772A5 (enExample) | ||
| JP2009533369A5 (enExample) | ||
| JP2013504593A5 (enExample) | ||
| JP2009525956A5 (enExample) | ||
| JP2009534339A5 (enExample) | ||
| CN111925381B (zh) | 一种巴洛沙韦关键中间体的合成方法 | |
| RU2012143523A (ru) | СПОСОБ И ПРОЦЕСС ПРИГОТОВЛЕНИЯ И ПРОИЗВОДСТВА ДЕЙТЕРИРОВАННОЙ ω-ДИФЕНИЛМОЧЕВИНЫ | |
| JP2020097607A (ja) | クロマノン誘導体の新規な製造方法 | |
| JP2014504599A5 (enExample) | ||
| JP2008540414A5 (enExample) | ||
| CN1662484A (zh) | 制备(r)芳氧基丙酸酯衍生物的方法 | |
| JP2004505097A5 (enExample) | ||
| JP2017513885A5 (enExample) | ||
| CN104910068B (zh) | 一种2‑氰基异烟酸酰肼1.5对甲苯磺酸盐的合成方法 | |
| US6914159B1 (en) | Process for preparing sulfamoyl-substituted phenethylamine derivatives | |
| CN111116420A (zh) | 一种对称脲类化合物的制备方法 | |
| CN111116421B (zh) | 一种酰胺衍生物的制备方法 | |
| JP2011506323A5 (enExample) | ||
| CN105399668B (zh) | 一种“一锅法”制备索拉菲尼的方法 | |
| JP2007126486A5 (enExample) | ||
| JP2005530847A5 (enExample) | ||
| JP2007503406A5 (enExample) | ||
| JP2004026660A5 (enExample) |